Radiopharm Theranostics Ltd. reported its financial results for the first half of fiscal 2026 ended December 31, 2025. The company recorded net cash outflows from operating activities of USD 22.67 million during the period. Cash and cash equivalents stood at USD 34.52 million, providing a runway into 2027 to support the advancement of its radiotherapeutic pipeline through key clinical and regulatory milestones. In October 2025, Radiopharm Theranostics secured commitments to raise approximately USD 35 million via private placement from international and Australian institutional and industry investors. Payments to related parties during the half-year period encompassed remuneration for director fees to executive and non-executive directors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001161573-en) on January 28, 2026, and is solely responsible for the information contained therein.